Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.
Follow REGN
Regeneron Pharmaceuticals, Inc. (REGN) Shares outstanding
Regeneron Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $108.6M, down 5.65% from $115.1M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $106.0M. Over the past ten years it has ranged from $108.6M (fiscal 2025) to $116.3M (fiscal 2016) — the current reading is the lowest in ten years. Regeneron Pharmaceuticals, Inc. ranks 135th of 602 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $108.6M | (5.65%) |
| FY2024 | $115.1M | 1.23% |
| FY2023 | $113.7M | 0.18% |
| FY2022 | $113.5M | 1.16% |
| FY2021 | $112.2M | (2.52%) |
| FY2020 | $115.1M | 0.44% |
| FY2019 | $114.6M | (0.17%) |
| FY2018 | $114.8M | (0.95%) |
| FY2017 | $115.9M | (0.34%) |
| FY2016 | $116.3M | 0.93% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $106.0M | (1.58%) |
| Mar 2026 | $107.7M | (0.83%) |
| Dec 2025 | $108.6M | 1.31% |
| Sep 2025 | $107.2M | (1.29%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| RPRX Royalty Pharma PLC compare | $556.9M |
| MRNA Moderna, Inc. compare | $398.0M |
| VRTX Vertex Pharmaceuticals Incorporated compare | $255.2M |
| RVMD Revolution Medicines, Inc. compare | $210.9M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.3M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| REGN Regeneron Pharmaceuticals, Inc. | $106.0M |
| ARGX argenex SE compare | $64.5M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement